Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …

Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory
infection, lower respiratory tract disease, clinical complications, and death in older adults …

Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was
efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in≥ 60-years …

Background Respiratory syncytial virus (RSV) is an important cause of disease in older
adults. We evaluated the safety and immunogenicity of a stabilized RSV prefusion F subunit …

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions
are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness …

Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based …

Background Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in
older adults and adults with comorbidities. An effective vaccine is needed. An investigational …

ABSTRACT Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that
can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants …

Background Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …

Background Despite the high disease burden of respiratory syncytial virus (RSV) in older
adults, there is no approved vaccine. We evaluated the experimental RSV vaccine, Ad26 …